SCHEMBL17799644

SCHEMBL17799644

Cc1cocc1C(=O)N[C@H]1CC[C@H]1c1ccc(F)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAS1R3 Q7RTX0 3/20 0.41
▸ TAS1R1 Q7RTX1 3/20 0.41
▸ TAS1R2 Q8TE23 3/20 0.41
▸ ATM Q13315 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HCRTR1 O43613 2/20 0.36
▸ HCRTR2 O43614 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ MC4R P32245 1/20 0.36
▸ CNR1 P21554 2/20 0.35
▸ CNR2 P34972 2/20 0.35
▸ HTR2A P28223 1/20 0.35
▸ HTR2C P28335 1/20 0.35
▸ HTR2B P41595 1/20 0.35
▸ MC1R Q01726 2/20 0.35
▸ FPR1 P21462 1/20 0.35
▸ FPR2 P25090 1/20 0.35
▸ KLKB1 P03952 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17799656 0.84 HCRTR1 (0.50) TAS1R3TAS1R1TAS1R2HCRTR1HCRTR2
SCHEMBL17799732 0.82 ALDH1A1 (0.51) TAS1R3TAS1R1TAS1R2HPGDL3MBTL1
SCHEMBL17799692 0.80 HCRTR1 (0.49) TAS1R3TAS1R1TAS1R2HCRTR1HCRTR2
SCHEMBL17799662 0.80 TAS1R3 (0.43) TAS1R3TAS1R1TAS1R2HCRTR2HTR2A
SCHEMBL17799695 0.79 HCRTR1 (0.46) TAS1R3TAS1R1TAS1R2HCRTR1HCRTR2
SCHEMBL17799664 0.78 MC1R (0.43) TAS1R3TAS1R1TAS1R2HCRTR1HCRTR2
SCHEMBL17799706 0.77 TAS1R3 (0.39) TAS1R3TAS1R1TAS1R2HPGDHCRTR1
SCHEMBL17799700 0.77 HCRTR1 (0.49) TAS1R3TAS1R1TAS1R2HCRTR1HCRTR2
SCHEMBL17799733 0.77 HCRTR1 (0.50) TAS1R3TAS1R1TAS1R2HPGDHCRTR1
SCHEMBL17799707 0.77 SIGMAR1 (0.42) TAS1R3TAS1R1TAS1R2HPGDHCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50724-E1 4-membered ring carboxamides used as nematicides SYNGENTA CROP PROTECTION AG (CH) 2026-01-06 — — US disclosed
EP-3019476-B1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2018-01-17 — — EP disclosed
US-9867371-B2 4-membered ring carboxamides used as nematicides SYNGENTA PARTICIPATIONS AG (CH) 2018-01-16 — — US disclosed
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES TUBA3C, DDT, CYCS TAS1R3 3195/4885TAS1R1 3418/4885TAS1R2 2989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback